会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 71. 发明公开
    • SAFE SEQUENCING SYSTEM
    • 安全测序系统
    • EP3246416A1
    • 2017-11-22
    • EP17154750.8
    • 2012-04-12
    • The Johns Hopkins University
    • VOGELSTEIN, BertKINZLER, KennethPAPADOPOULOS, NickolasKINDE, Isaac
    • C12Q1/68C12N15/11
    • C12Q1/6874C12Q1/6806C12Q1/6869C12Q1/6876C12Q2563/179C12Q2600/158C12Q2535/122C12Q2565/514
    • The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called "Safe-SeqS" for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant ("super-mutants") if =95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.
    • 存在于一小部分DNA模板中的突变的鉴定对于生物医学研究的若干领域的进展是必不可少的。 尽管大规模并行测序仪器原则上非常适合于此任务,但这些仪器的错误率通常太高,以至于无法确定罕见变体。 我们在这里描述了一种可以大幅度提高大规模并行测序仪器的灵敏度的方法。 这种方法的一个例子叫做安全测序系统(Safe-Sequencing System)的“Safe-SeqS”,包括(i)为每个模板分子分配一个唯一标识符(UID) (ii)扩增每个独特标记的模板分子以产生UID家族; 和(iii)扩增产物的冗余测序。 具有相同UID的PCR片段确实是突变体(“超级突变体”),如果其中95%含有相同的突变。 我们说明了这种方法用于确定聚合酶保真度的效用,体外合成的寡核苷酸的准确性以及正常细胞核和线粒体基因组突变的发生率。
    • 74. 发明公开
    • DIFFERENTIAL IDENTIFICATION OF PANCREATIC CYSTS
    • 孢囊区分性鉴定
    • EP2780473A1
    • 2014-09-24
    • EP12849091.9
    • 2012-11-12
    • The Johns Hopkins University
    • VOGELSTEIN, BertKINZLER, Kenneth W.PAPADOPOULOS, NickolasWU, JianHRUBAN, RalphMAITRA, AnirbanDAL MOLIN, Marco
    • C12Q1/68C12N15/11
    • C12Q1/6886C12Q1/6883C12Q2600/156
    • More than 2% of adults harbor a pancreatic cyst, a subset of which progress to invasive lesions with lethal consequences. To assess the genomic landscapes of neoplastic cysts of the pancreas, we determined the exomic sequences of DNA from the neoplastic epithelium of eight surgically resected cysts of each of the major neoplastic cyst types: serous cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs) and solid pseudo-papillary neoplasms (SPNs). SPNs are low-grade malignancies, and IPMNs and MCNs, but not SCAs, have the capacity to progress to cancer. We found that SCAs, IPMNs, MCNs, and SPNs contained 10 = 4.6, 27 = 12, 16 = 7.6, and 2.9 = 2.1 somatic mutations per tumor, respectively. Among the mutations identified, E3 ubiquitin ligase components were of particular note. Four of the eight SCAs contained mutations of VHL, a key component of the VHL ubiquitin ligase complex that has previously been assoCiated both with renal cell carcinomas, SCAs, and other neoplasms. Six of the eight IPMNs and three of the eight MCNs harbored mutations of RNF43, a gene coding for a protein with intrinsic E3 ubiquitin ligase activity that has not previously been found to be genetically altered in any human cancer. The preponderance of inactivating mutations in RNF43 unequivoCally establish it as a suppressor of both IPMNs and MCNs. SPNs contained remarkably few genetic alterations, but always contained mutations of CTNNB1, previously demonstrated to inhibit degradation of the encoded protein (ß-catenin) by E3 ubiquitin ligases. These results highlight the essential role of ubiquitin ligases in these neoplasms and have important implications for the diagnosis and treatment of patients with cystic tumors.
    • 75. 发明公开
    • SAFE SEQUENCING SYSTEM
    • 安全测序系统
    • EP2697397A2
    • 2014-02-19
    • EP12772013.4
    • 2012-04-12
    • The Johns Hopkins University
    • VOGELSTEIN, BertKINZLER, Kenneth W.PAPADOPOULOS, NickolasKINDE, Isaac
    • C12Q1/68C12N15/11
    • C12Q1/6874C12Q1/6806C12Q1/6869C12Q1/6876C12Q2563/179C12Q2600/158C12Q2535/122C12Q2565/514
    • The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called "Safe-SeqS" for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant ("super-mutants") if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized
      in vitro , and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.
    • 存在于一小部分DNA模板中的突变的鉴定对于生物医学研究的若干领域的进展是必不可少的。 尽管大规模并行测序仪器原则上非常适合于此任务,但这些仪器的错误率通常太高,以至于无法确定罕见变体。 我们在这里描述了一种可以大幅度提高大规模并行测序仪器的灵敏度的方法。 这种方法的一个例子叫做安全测序系统(Safe-Sequencing System)的“Safe-SeqS”,包括(i)为每个模板分子分配一个唯一标识符(UID) (ii)扩增每个独特标记的模板分子以产生UID家族; 和(iii)扩增产物的冗余测序。 具有相同UID的PCR片段如果≥95%含有相同的突变,则是真正的突变体(“超级突变体”)。 我们说明了这种方法用于确定聚合酶保真度的效用,体外合成的寡核苷酸的准确性以及正常细胞核和线粒体基因组突变的发生率。